Category Archives: Biotechnology

Barron's

Earnings Preview: Biotechnology Looks Healthy Barron's The iShares Nasdaq Biotechnology (IBB) has climbed 0.34%. Meanwhile the SPDR S&P Biotech ETF (XBI) has declined 0.21%. IBB could be benefiting from having a wider swath of companies, in addition to the fact that the average market cap of its index ... and more »

Originally posted here:
Earnings Preview: Biotechnology Looks Healthy - Barron's

Post Analyst

-$1.86 Earnings Per Share Expected for Puma Biotechnology Inc (PBYI) This Quarter The Cerbat Gem Puma Biotechnology logo Equities research analysts expect Puma Biotechnology Inc (NYSE:PBYI) to post earnings per share of ($1.86) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Puma Biotechnology's ... Consensus Analysts Roundup on Puma Biotechnology, Inc. (NYSE:PBYI) Ocular Therapeutix, Inc. (NASDAQ:OCUL)Davidson Register Puma Biotechnology Inc (PBYI) Receives $70.50 Average PT from ...Chaffey Breeze Puma Biotechnology (PBYI) Given Media Sentiment Score of 0.02Markets Daily Post Analyst -TCT -Street Updates all 13 news articles »

Read the original:
-$1.86 Earnings Per Share Expected for Puma Biotechnology Inc (PBYI) This Quarter - The Cerbat Gem

Barron's (blog)

Earnings Preview: Biotechnology Looks Healthy Barron's (blog) The iShares Nasdaq Biotechnology (IBB) has climbed 0.34%. Meanwhile the SPDR S&P Biotech ETF (XBI) has declined 0.21%. IBB could be benefiting from having a wider swath of companies, in addition to the fact that the average market cap of its index ... and more »

See original here:
Earnings Preview: Biotechnology Looks Healthy - Barron's (blog)

Breaking Finance News

iShares NASDAQ Biotechnology Index (IBB) Earning Very Favorable Media Coverage, Report Shows The Cerbat Gem iShares NASDAQ Biotechnology Index logo Media stories about iShares NASDAQ Biotechnology Index (NASDAQ:IBB) have been trending very positive recently, according to AlphaOne Sentiment Analysis. The research group, a subsidiary of Accern, ... iShares NASDAQ Biotechnology Index (IBB) Stock Rating Upgraded by Vetr Inc.BBNS iShares NASDAQ Biotechnology Index (IBB) Upgraded to "Buy" by Vetr Inc.Markets Daily iShares NASDAQ Biotechnology Index (IBB) Upgraded to Buy by ...Community Financial News ETF Trends -Breaking Finance News -Investopedia all 12 news articles »

Read more from the original source:
iShares NASDAQ Biotechnology Index (IBB) Earning Very Favorable Media Coverage, Report Shows - The Cerbat Gem

Post Analyst

Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of -$1.86 Per Share Sports Perspectives Puma Biotechnology logo Wall Street analysts predict that Puma Biotechnology Inc (NYSE:PBYI) will announce earnings per share of ($1.86) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Puma Biotechnology's ... Analyst Views On Top Movers In Recent Trade: Puma Biotechnology, Inc. (PBYI), Amedica Corporation (AMDA)Post Analyst The Puma Biotechnology Inc (PBYI) Shares Bought by Highbridge Capital Management LLCPetro Global News 24 Well recognized Stock of Market: Puma Biotechnology, Inc.'s (PBYI) stock price is Worth at $34.10 while ends ...Hot Stocks Point Community Financial News -MilTech all 9 news articles »

See the article here:
Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of -$1.86 Per Share - Sports Perspectives

In terms of pure biotechnology, Europe has embraced innovation. However, it cannot compete with the US yet because it cannot drive private investment in the field, as well as open up the market to new products, a pharmaceutical executive told EURACTIV.com in Lyon.

Despite the EUs consistent growth in the biotech business, the EBE claims that the industry is not receiving enough support from investors, universities or research institutions, thus limiting the EUs ability to keep pace with the US in biotechnology.

The EU is lagging behind due to challenges in translating scientific innovations into successful businesses, a European Biopharmaceutical Enterprises (EBE) report claims.

Biotechnology is the use of living systems or organisms in the creation of industrial products. The growth of the biotechnology industry is important for Europe and created 10,000 new jobs and 93 medicines recommended for market authorisation by the European Medical Agency in 2015, according to the EBE.

Biotechnology could help patients across Europe gain access to innovative therapies, for example, against rare diseases. Proponents of bio-medicines also claim that precision therapy, because it is more efficient, will ease the burden on member states ailing healthcare systems.

The EBE suggests that steps should be taken to create a stronger investor community for biotech products to prevent places other than Europe from benefitting economically from technology invented and developed in Europe.

License to fail

The paper suggests that European entrepreneurs may be more adverse to risk because they have no license to fail, citing the lack of a strong culture of institutions or individuals seeking useful application of their work, taking out patents and creating start-up companies.

On the other hand, universities in the US often empower scientists to be knowledgeable in business and management.

The paper recommends that European institutions improve their support of scientists in marketing their technologies through better investment in Technical Transfer Offices (TTOs). The current lack of funding for TTOs at European universities means it is difficult for them to attract and train experienced staff.

Although Europe has public research funding organisations, such as the Innovative Medicines Initiative (IMI) and the European Commissions Horizon 2020, the lack of mature biotech companies makes the investment ecosystem fragile and makes it difficult for Europe to compete with the US for funding, the paper says.

Europe needs to build a bigger and better capital market for biotech companies to overcome the funding gap that prevents the needed growth of the biotech sector, it reads. The EBE suggests the European Commission create a single capital market for biotech companies and the creation of tax incentives for investment in biotechnology.

Being successful in the US

Didier Hoch, chairman of the Biovision 2017- The World Life Sciences Forum in Lyon, told EURACTIV that there are several reasons why biotechnology can flourish more easily in the US than in Europe.

According to Hoch, in terms of pure biotechnology, Europe is not lagging behind the US, as its sufficiently innovative. Where we are lagging behind is to drive investment in the field and attract private investors and open up the market to new products, he noted.

In fact, in the US the norm is to have a connection between the science, universities and private investors [] which is not yet the case in Europe, where there is a kind of fear when you are in the public sector to go private said Hoch, adding that another hindrance is the lack of trust between the public and private sector

Another difference between Washington and Brussels is the source of money. Hoch explained that money invested in the US biotech sector was coming from private investors, while in Europe, it comes from venture capital funds mainly funded by the EU institutions.

Even venture capitals are funded from EU money. This regime could eventually be thestrength for Europe, as in a way it can be competitive against private US money, he emphasised.

However, Hoch insisted that Europe still needed to convince more private sector entities to invest in biotechnology. It might be a long-term and risky field, but in the US the private sector invests in its potential, he said.

Hoch stressed that currently a biotech product could be considered successful if it has accessed the US market.

If you have a biotech company you should have in mind first to succeed in the US, even if you are based in Europe, he explained, explaining that in terms of the market, 70% of a new products success is in the US.

If you dont get your product there you will face difficulties, he said, emphasising that its mainly a political decision to have the US as an attracting market.

Last but not least, Hoch pointed out that its easier to get to the US market because there is a clear way to access and not like 27 different in the Europe, which have a country-based approach.

Making Europe innovative

In February, the centre-right European Peoples Party (EPP) presented its vision for the future of the Economic and Monetary Union (EMU) and emphasised the need for anew framework on access to financing in order for innovative companies to be encouraged to invest in Europe.

EPP President Joseph Daul told EURACTIV that the EU should become an innovation hub as this is the key to future growth and help it compete with the US.

This is where we need to concentrate our efforts to make Europe the worlds best talent hub. We should embrace radical innovations and make our continent the birthplace of the next Facebook or Apple, he told EURACTIV.

The EPP recognises that Europe was lagging behind compared to the US regarding innovative companies and, therefore, suggested the creation of an environment that will help new talents flourish.

We must understand that this follows partly from structural factors in our continent compared to our partners on the other side of the Atlantic. Venture Capital Funds in the EU are on average small. We need to support creating Funds of Funds, and we must look into existing regulations to make sure that investing in private equity funds is not discouraged by regulations and capital rules, the paper reads.

See original here:
Europe's biotechnology potential hindered by investment fears - EurActiv

Iran has made a considerable breakthrough in biotechnology inasmuch as it is able to produce GM foods and Up until 2013 it has produced 18 different kinds of recombinant medicines.

The modern biotechnology has been established nearly nine decades ago in Iran, started with vaccine production in Pasteur and Razi Institutes in 1920 and 1925. National Institute of Genetic Engineering and Biotechnology institute of Iran was established in 1989. Iranian scientists are active in various spheres of agriculture in this institute and work on medicinal plants with the aim of using their metabolites or increasing their tolerance to non-biological changes such as salinity or drought. One of the uses of biotechnology is in production of genetically modified foods; however, there are many opposing voices claiming that they are harmful for health.

Simply said, biotechnology harnesses cellular and bi molecular processes and puts them to work for us. It is used for production of GM foods and treating diseases with genetic technologies and many other fields. Biotechnology is an efficient, up-to-date and effective tool in agricultural field. Biotechnology helps you to improve plants' resistance to a considerable amount. Iran is among pioneering countries in this field. Up until 2013, 18 different kinds of recombinant drugs have been produced in Iran. This number is against 50 recombinant drugs produced globally. With the help of biotechnology and recombinant drugs, Iran has seen a 30% drop in its drug export and 50% inflation growth has been controlled.

Visit link:
PressTV-Biotechnology in Iran - Press TV

The UF business incubator Sid Martin Biotechnology Institute was named the 2017 Top Global Incubator of the Year.

The International Business Innovation Association recognized the institute March 28, said Mark Long, the institutes director. The institute received $1,500 for winning the award out of 30 other incubators.

The biotechnology institute provides lab space, equipment, business and legal advice at a low cost for new biotech companies, Long said.

Scientists need help understanding business and addressing the market, he said. Were here to help them out with that.

The institutes 40,000 square foot facility is at Progress Park in Alachua. Its used as office and laboratory space thats rented out to new companies unable to afford commercial space.

Getting an award like this is a real marketing tool in attracting new companies and investors for these companies, Long said.

He said since the institute started in 1995, businesses theyve served have a 78 percent success rate, meaning 78 percent of businesses stay open after the first five years. Since 2003, the success rate has improved to 93 percent.

Meekah Chaderton, a manager at the startup food development company Captozyme, said the institute helped improve the companys business.

Chaderton said Captozyme plans to move out of the institute and into their own space in June.

Small companies cant afford to buy a lot of equipment and lab space, so renting affordable space from Sid Martin has made us more competitive, Chaderton said.

View original post here:
UF biotechnology institute named Incubator of the Year - The Independent Florida Alligator

SAN FRANCISCO--(BUSINESS WIRE)--

DevonWay, Silicon Valleys leading provider of continuous improvement software to large enterprises, announced today its expansion into a new industry with the adoption of a global, Fortune 500 biotechnology client.

Biotechs emphasis on safety, quality, reliability, and innovation make it a natural fit for DevonWay software, which is in widespread use by global construction companies, utilities, and government agencies.

Its an exciting time to be a part of biotech, said DevonWay CEO Chris Moustakas, and were thrilled to serve an industry that has such a huge impact on public health, disease prevention, and treatment. One of the challenges facing biotech today is maintaining a culture of innovation, which feeds the industrys rapid growth, while never sacrificing quality or safety. Were grateful for the opportunity to help the industry meet this challenge head-on.

Although many biotechnology companies use Quality Management Systems to help ensure quality and regulatory compliance, those systems often lack the flexibility needed to handle specific operational requirements. Continuous improvement software, such as that provided by DevonWay, is purpose-built to bridge the gap between operations and quality, and can serve the needs of both in a single closed-loop, FDA 21CFR11-compliant system.

Whether were brought on board to complement an existing QMS or outright replace it, our first and foremost priority is to serve the needs of our customers, says Matt Sacks, DevonWays Vice President of Sales. Unlike most systems currently servicing life sciences, our products can evolve without having to modify code. In an industry in which change is constant, this ability to facilitate change quickly and cost effectively provides a crucial advantage to our customers.

About DevonWay

Founded in San Francisco in 2005, DevonWay is a leading provider of continuous improvement and digital operations applications to customers across industries as diverse as energy generation, transmission and distribution, government, life sciences, and construction. By combining flexibility with ease of use, DevonWay helps high-reliability organizations transform, digitize, and continuously improve their operations.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170404006173/en/

The rest is here:
DevonWay Inc. Expands into Biotechnology Industry - Yahoo Finance

NEW YORK, April 3, 2017 /PRNewswire/ -- Use this report to: - Explore present and future strategies within the bioseparation systems market. - Learn about the upcoming developments, the holdups and the needs of the market. - Gain an insight into acquisition strategies and collaborations by companies.

Read the full report: http://www.reportlinker.com/p0619255/Separation-Systems-for-Commercial-Biotechnology.html

- Receive an overview of the relevant patents related to the industry.

Highlights - The global market for bioseparation reached $18.4 billion in 2015. This market is expected to increase from $19.0 billion in 2016 to nearly $24.0 billion in 2021 at a compound annual growth rate (CAGR) of 4.7% for 2016-2021. - United States market for bioseparation is expected to grow from $7.0 billion in 2016 to nearly $9.3 billion at a CAGR of 5.9% from 2016 through 2021. - Emerging market for bioseparation is expected to grow from $7.0 billion in 2016 to $8.7 billion in 2021 at a CAGR of 4.4% from 2016 through 2021.

Introduction & Scope

Introduction

Study goals and objectives In recent years, the bioseparation systems (separation systems in biotechnology) segment has been one of growth in the biopharmaceuticals market. Primary use of these systems is for separation and purification of biological products. BCC Research's goal in conducting this study is to provide an overview of the current and future characteristics of the global market for various bioseparation systems. This report explores present and future strategies within the bioseparation systems market. The market is categorized into liquid chromatography, centrifugation, electrophoresis, membrane filtration, flow cytometry, microarray, labonachip, biochip, and magnetic separation. The upcoming developments of the market, the holdups and the needs of the market are discussed in this report. The classifications, comparisons and usage of these products are also portrayed in this report. A detailed analysis of the structure of the bioseparation systems industry has been conducted. The revenues have been broken down by region and sales figures are estimated for the fiveyear period from 2016 through 2021. The report also covers significant patents and their allotments in each category.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type in light of new technologies, growing competition, and changing customer needs.

Reasons for doing this study Bioseparation systems have a major place in the biopharmaceutical and biotechnology industry. Bioseparation is conducted on biological products like proteins, nucleic acids, and cell cultures, among others. The increasing demand for biopharmaceutical products is driving the global market for bioseparation systems. Increased research in life sciences, newer technological developments are taking bioseparation techniques to prodigious heights. Modern industries have now begun to explore the advantages of bioseparation systems in their production processes, which have led to a steady market. Research and development (R&D) spending, along with increasing competition and patent expiries are giving a new direction to the market. This study looks at almost all the systems affected by these factors.

Contributions of the study and for whom This study contributes to the areas of market growth for the manufacturers and users of bioseparation systems. Genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies will find this study to be of interest.

Scope of report The market for bioseparation systems is growing rapidly across all regions. Bioseparation purifies biological products on a largescale. The report focuses on the global market of bioseparation systems and provides an updated review, including basic design and its applications, in various arenas of biomedical and life science research. The scope of the study is global. BCC Research analyzes each market, new products and advancements, technologies involved, market projections and market shares. The geographical regions covered in the report are North America, Europe and emerging markets. The emerging market covers all countries like India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, and Canada, among others. The bioseparation techniques that are covered in this report are chromatography, centrifugation, electrophoresis, membrane filtration, flow cytometry, microarray, labonachip, biochip, and magnetic separation. Among chromatography techniques, liquid chromatography is the most active market.

Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead the bioseparation systems market. Key players include Thermo Fisher Scientific, Agilent Technologies Inc., BioRad Laboratories, Danaher Corp., Qiagen N.V., Merck KGaA GmbH, and Waters Corp. among others.

Information sources Many companies were surveyed to obtain data for this study. Included were manufacturers and end users of bioseparation systems. Data was gathered from various industry sources. BCC Research spoke with officials within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade, and government sources.

Methodology Read the full report: http://www.reportlinker.com/p0619255/Separation-Systems-for-Commercial-Biotechnology.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/separation-systems-for-commercial-biotechnology-300433779.html

Excerpt from:
Separation Systems for Commercial Biotechnology - Yahoo Finance